Attached files
file | filename |
---|---|
EX-99.1 - PROTECT PHARMACEUTICAL Corp | v206788_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (date of earliest event reported): December 23, 2010
PROTECT
PHARMACEUTICAL CORPORTION
(Exact
name of registrant as specified in its charter)
NEVADA
|
000-54001
|
27-1877179
|
(State
or other jurisdiction
|
(Commission
|
(IRS
Employer
|
of
incorporation)
|
File
Number)
|
Identification
No.)
|
116
Village Boulevard, Suite 200, Princeton, New Jersey 08540
(Address
of principal executive offices)
Registrant's
telephone number, including area code: (609) 945-3938
759 Bloomfield Ave., Suite 411, West Caldwell, New Jersey
07006
(Former name or former
address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
FORM
8-K
Item
5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Mr. William D. Abajian has resigned as
a director of Protect Pharmaceutical Corporation and as the company’s President,
Chief Executive Officer and Treasurer, effective December 23,
2010. Mr. Abajian stated in his letter to the Board that because of
certain recent events, he believed he would not be allowed to perform his duties
in the manner he deemed necessary to serve the best interest of the company and
its shareholders. Mr. Abajian has noted that his disagreement was
with the company’s Chief Operating Officer and director, Ramesha
Sesha. No replacement for Mr. Abajian has been named as of this
date.
Also on December 23, 2010, Dr. Gerald
Bernstein resigned his position as a director of the company for personal
reason. His resignation was effective immediately. No
replacement for Dr. Bernstein has been named as of this date.
Notes
about Forward-looking Statements
Statements contained in this current
report which are not historical facts, may be considered "forward-looking
statements," which term is defined by the Private Securities Litigation Reform
Act of 1995. Forward-looking statements are based on current
expectations and the current economic environment. We caution readers
that such forward-looking statements are not guarantees of future performance.
Unknown risks and uncertainties as well as other uncontrollable or unknown
factors could cause actual results to materially differ from the results,
performance or expectations expressed or implied by such forward-looking
statements.
Item
9.01 Financial Statements and Exhibits
(c)
Exhibits
Exhibit
No. Description
99.1 Letter
from William D. Abajian dated December 23, 2010
______________
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
Protect Pharmaceutical Corporation | |||
Date: December
29, 2010
|
By:
|
/S/ Ramesha Sesha | |
Ramesha Sesha | |||
Chief Operating Officer |
-2-